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In Japan, lung cancer is the leading cause of cancer death in men
and the second leading cause, after stomach carcinoma, in women.
Lung cancers are classified into several groups, including small-
cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC).
Although the most successful treatment for the latter group is
surgical removal of the tumour, the average 5-year survival rate
after complete resection is approximately 60—85%, 45% and 30%
for stage I, II and IIIA disease respectively (Mountain, 1993). In
addition, there is a marked variation in outcome among different
individuals. Thus, it is desirable to obtain additional information
on the phenotype and pathology of lung cancer to aid characteriza-
tion of these tumours.
Tissue factor (TF) is a normal component of the haemostatic
system. Initiation of blood coagulation is efficiently mediated by
TF, the cell-surface receptor for the coagulation zymogen factor
VII (FVII) and the receptor and co-factor for the serine protease
factor VIIa (FVIIa). Protein—protein interactions between FVIIa
and TF are considered essential for the co-factor functions, which
involve the catalytic enhancement of FVIIa-mediated proteolytic
activation of the zymogen substrates factors X and IX (Nemerson,
1988). TF is normally expressed in the adventitial layer and
mesenchymal-appearing cells of large blood vessels (Drake et al,
1989; Wilcox et al, 1989), providing a barrier against blood loss
into the extravascular space.
Although TF has also been found in several types of neoplastic
cells (Callander et al, 1992), and there appears to be a relationship
between TF expression and the metastatic properties of tumours
(Mueller et al, 1992), we have little information on TF expression
in lung cancer, especially in NSCLC. In this study, we first
examined NSCLC cells in culture and assessed the expression of
TF by means of functional study, Western blot analysis and
immunocytochemical staining. We then used a sensitive enzyme-
linked immunosorbent assay (ELISA) to quantitate TF antigen
(Ag) in a wide variety of lung cancer cell lines and examined
whether the levels of TF are associated with the characteristics of
the original tumour. We also immunohistochemically investigated
the expression of TF in fresh-frozen specimens of lung cancers.
MATERIALS AND METHODS
Lung cancer cell lines and cell characteristics
Eight cell lines of human NSCLC were provided by the Health
Science Research Resources Bank: five cell lines derived from
adenocarcinoma (PC-3, ABC-1, RERF-LC-OK, RERF-LC-MS,
and A549) and three from squamous cell carcinoma (EBC-1, LC-
1sq, and LK-2). The characteristics of the cancer cells are shown in
Table 1 (Smith et al, 1977; Hiraki et al, 1982; Itoh et al, 1991;
Kishimoto et al, 1992). The cancer cells were maintained in
Dulbecco￿s modification of Eagle￿s minimum essential medium or
in RPMI-1640 with 10% heat-inactivated fetal bovine serum (FBS).
TF and anti-TF antibodies
Recombinant human TF and mouse monoclonal antibodies
(mAbs) (TF8-5G9 and TF9-6B4) specific for human TF were
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obtained from Corvas International (San Diego, CA, USA).
Human placental TF was obtained from Behringwerke
(Thromborel S, Marburg, Germany). Mouse mAbs (ADI 4504 and
4509) and rabbit polyclonal antibody (pAb) (ADI 4502) specific
for human TF were obtained from American Diagnostica
(Greenwich, CT, USA). The specificity of these mAbs has been
described in detail elsewhere (Morrissey et al, 1988; Ruf and
Edgington, 1991; Ruf et al, 1991). Antigenic TF expression
detected immunohistochemically with the use of these TF-specific
mAbs (ADI 4504 and 4509) was reported to be correlated with
functional TF expression (Contrino et al, 1994).
Analysis of procoagulant activity in clotting assay
Confluent lung cancer cells in 100-mm culture dishes were
suspended in phosphate-buffered saline (PBS, pH 7.4) and the
suspensions were adjusted to 1 ´ 106 cells ml—1 in PBS. Cell suspen-
sions to be evaluated for total cellular procoagulant activity were
frozen and thawed three times and sonicated. Cell suspension
(0.1 ml, 1 ´ 105 cells) was added to 0.1 ml of pooled human normal
plasma. After incubation at 37°C for 2 min, 0.1 ml of 25 mmoll—1.
CaCl2 was added and plasma recalcification time was determined
with a semiautomatic coagulometer (CA-100, Sysmex, Kobe,
Japan). TF co-factor activity was quantitated by reference to stan-
dard curves constructed with placental TF. TF activity yielding a
50-s recalcification time was defined as 1 unit per ml. The values
given are the means ± s.d. for quadruplicate samples.
Neutralization test
Each lung cancer cell suspension (0.5 ml) was mixed and incu-
bated with an equivalent volume of anti-TF mAb, ADI 4509, at a
concentration of 50 mg ml—1 at 37°C for 1 h. The clotting time of
each mixture was measured by the recalcification method as
described above. Control assays were performed with the use of
preimmune mouse IgG.
Immunoblotting analysis
Confluent lung cancer cells in 100-mm culture dishes were rinsed
with PBS three times and disrupted by incubation with 0.5%
Triton X-100 in PBS for 60 min. Clear lysates were then obtained
by centrifugation for 5 min at 7000g. These samples were
subjected to 12.5% sodium dodecyl sulphate polyacrylamide gel
electrophoresis (SDS-PAGE) under reducing conditions. As
protein content may vary greatly among cell lines, we adjusted the
cell number, instead of the protein content, for SDS-PAGE. The
lysates from 1.0 ´ 105 cells were applied on each lane. Purified
recombinant TF and placental TF were used as positive controls.
After separation by SDS-PAGE, these samples were electrophoret-
ically transferred to polyvinylidene difluoride membranes
(Immobilon-P, Millipore Corp., Bedford, MA, USA). The trans-
ferred membranes were then blocked by incubation in PBS
containing 5% low-fat milk for 1 h, washed in the washing buffer
and incubated with the appropriate mAb (TF8-5G9, ADI 4509 and
a mixture of all mAbs described above) overnight. After washing,
the membranes were incubated with peroxidase-conjugated anti-
mouse IgG (Bio-Rad Laboratories, Hercules, CA, USA) for 1 h,
followed by the addition of 3-3¢-diaminobenzidine hydrochloride
as substrate.
Table 1 Levels of tissue factor in cell lines derived from human non-small-cell lung cancer
Characteristics of original tumour Tissue factor (ng 10–6 cells)
Histological Clinical Source Cell lysate Culture medium
type stage
Adenocarcinoma
PC-3 P/D Ad IV Lymph node 130.68 ± 11.06 6.70 ± 0.65
ABC-1 W/D Ad IV Pleural effusion 70.55 ± 5.00 8.69 ± 1.34
RERF-LC-OK Ad Pleural effusion 19.46 ± 0.94 0.82 ± 0.16
RERF-LC-MS Ad Pleural effusion 16.20 ± 1.06 1.44 ± 0.10
A549 W/D Ad I Primary lesion 0.10 ± 0.02 0.01 ± 0.01
Squamous cell carcinoma
EBC-1 P/D Sq IV Skin metastasis 4.52 ± 0.38 0.82 ± 0.05
LC1sq P/D Sq I Primary lesion 0.42 ± 0.04 0.12 ± 0.03
LK2 P/D Sq I Primary lesion 0.17 ± 0.01 0.04 ± 0.01
P/D, poorly differentiated; W/D, well differentiated; Ad, adenocarcinoma; Sq, squamous cell carcinoma; TF Ag in the cell lysates and soluble TF Ag in the culture
media were measured by ELISA. TF Ag level is expressed as mean ± s.d. See Materials and methods for details.
Table 2 Tissue factor expression in surgically resected non-small-cell lung
cancers
Characteristics Number of positive/total number tested
Total 46/55
Male 31/36
Female 15/19
Histological type
Adenocarcinoma 32/38
Well differentiated 10/12
Moderately differentiated 13/16
Poorly differentiated 9/10
Squamous cell carcinoma 12/15
Well differentiated 3/3
Moderately differentiated 2/2
Poorly differentiated 7/10
Large-cell carcinoma 2/2
Pathological stage
Stage I 17/24
Stage II 5/5
Stage IIIA 17/17
Stage IIIB 5/5
Stage IV 2/4474 M Sawada et al
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Immunocytochemical staining of TF from cultured
human lung cancer cell lines
Lung cancer cells were cultured in culture plates (LAB-TEK,
Miles Scientific, Elkhart, IN, USA), and the plates were washed
with PBS three times. After the cells were fixed in methanol, the
plates were incubated with 3% hydrogen peroxide in methanol for
5 min to block endogenous peroxidase activity. The plates were
treated with 5% bovine serum albumin (BSA) and incubated with
the appropriate mAb, TF8-5G9, overnight at 4°C. They were then
washed with PBS, and mAb binding was visualized with the
labelled streptavidin—biotin method (Dako, Carpinteria, CA,
USA). The specificity of immunostaining was confirmed by nega-
tive control, using non-immune mouse IgG in place of the primary
mAb and by preabsorption of each mAb with the placental TF
(50 ´ molar excess).
Measurement of TF antigen in cell lysates and culture
media
Lung cancer cells were plated at a density of 0.7—1.0 ´ 105 cells
per well and grown for 4 days in 24-well culture plates at 37°C in
a humidified atmosphere of 5% carbon dioxide in air. The culture
medium was centrifuged at 1500 r.p.m. for 10 min and the super-
natant was used for the assay of TF levels in the culture medium.
Cell pellets in the plate were washed with PBS three times and
disrupted by incubation with 400 ml of 0.5% Triton X-100 in
PBS for 60 min. Then, the plates were centrifuged at 2500 r.p.m.
for 20 min, and the supernatant of the cell lysates was analysed for
TF levels.
Total TF Ag in the cell lysates and soluble TF Ag in the culture
media were measured by ELISA using two anti-TF mAb, TF8-
5G9 and TF9-6B4, as previously described (Koyama et al, 1994).
TF concentration was determined in four samples of each cell line.
The cell number was counted in four samples of each cell line and
TF Ag level was expressed in terms of ng per 106 cells.
Immunohistochemical studies of clinical specimens
A total of 55 patients with lung cancer who underwent lung resec-
tion at Tokyo Medical and Dental University or Teishin Hospital
from August 1992 to January 1997 were studied (Table 2).
Histological diagnoses were made on the basis of sections stained
with haematoxylin and eosin. The specimens included 38 adeno-
carcinomas, 15 squamous cell carcinomas and two large-cell carci-
nomas. The pathological staging of each tumour was determined
according to the TNM system (Hermanek and Sobin, 1992). The
classification of staging in the patients was as follows: stage I, 24
patients; stage II, 5 patients; stage IIIA, 17 patients; stage IIIB, 5
patients; stage IV, 4 patients. Three of the 17 stage IIIA patients
were T3N0M0. Therefore, of the 55 patients, 27 had neither
hematogenous nor lymphogenous metastasis. None of the patients
had received chemotherapy before surgery. Informed consent for
lung resection was obtained from all patients. Immediately after
lung resection, tissue samples were embedded in OCT compound
(Tissue-Tek, Miles Scientific, Elkhart, IN, USA) and frozen in
liquid nitrogen for cryostat sectioning. For immunohistochemical
examination, 6-mm-thick cryostat sections were fixed in cold
acetone for 5 min or in 2% paraformaldehyde for 1 h and staining
was performed in a similar manner as described for immunocyto-
chemical staining with TF-specific mAb (TF8-5G9, ADI 4504 and
4509) and pAb (ADI 4502).
All specimens were read blind by two experienced pathologists.
The specimens were compared with negative controls, and the
percentage of positively stained neoplastic cells was estimated.
The results were graded as follows: negative (—), completely nega-
tive; moderately positive (+), the percentage of positive neoplastic
cells was under 90%; and strongly positive (++), the percentage of
positive neoplastic cells was 90% or higher.
Statistical analysis
The data were analysed with the chi-square test, and P values less
than 0.05 were considered to indicate statistical significance.
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Figure 1 Western blot analysis of lung cancer cells with anti-TF Ab.
Detergent-soluble protein samples of lung cancer cells were analysed on a
12.5% SDS-polyacrylamide gel using a mixture of mAbs against TF. The
molecular size markers used were b-galactosidase (126 kDa), bovine serum
albumin (71 kDa) and carbonic anhydrase (41.8 kDa). Positions of the
markers are indicated by arrows. The mixture of anti-TF mAbs identified the
reduced form of recombinant TF as multiple bands at approximately 36–46
kDa (lane 2) and placental TF at 48 kDa (lane 1). TF detected in PC-3 cells
producing high levels of TF on ELISA exhibited several intense bands
distributed from about 46–64 kDa (lane 3), whereas TF in ABC-1 was
determined as a doublet at approximately 46 kDa and 49 kDa (lane 4)
Figure 2 Immunocytochemical staining for TF in cultured human lung
cancer cell lines. Positive staining is indicated by the dark-brown reaction
products. The presence of TF along the cell membrane is clearly
demonstrated in adenocarcinoma cell line, ABC-1 (´ 400)TF in non-small-cell lung cancer 475
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RESULTS
Procoagulant activity of lung cancer cells and
neutralization test
Procoagulant activities of three adenocarcinoma cell lines were
determined by the recalcification time. Procoagulant activities
were 45.1 ± 0.8 U ml—1, 0.6 ± 0.07 U ml—1, and 0.06 ± 0.01 U ml—1
for PC-3, ABC-1, and A549 respectively. These procoagulant
activities were neutralized by preincubation of cells with an anti-
TF mAb (99.5% inhibition for PC-3 and 99.1% for ABC-1),
showing that TF contributes to the cell procoagulant status.
Western blot analysis of lung cancer cell lysates with
anti-TF Ab
The presence of TF in lung cancer cells (PC-3 and ABC-1 from
adenocarcinoma) was determined by immunoblotting with the
mAb specific for human TF (Figure 1). The mAbs (ADI 4509 and
TF8-5G9) and the mixture of all mAbs described above identified
the reduced form of recombinant TF as multiple bands at approxi-
mately 36 kDa to 46 kDa and a minor 75-kDa band, which may
represent a dimeric form, and placental TF at 48 kDa. TF in
ABC-1 appeared as a doublet at about 46 kDa and 49 kDa, which
is similar to the size of placental TF, whereas TF detected in PC-3
cells producing high levels of TF on ELISA exhibited several
intense bands distributed from about 46 to 64 kDa.
The recombinant TF used in this study was synthesized by
Chinese hamster ovary (CHO) cell lines. Although recombinant
human TF expressed in Escherichia coli lacks post-translational
disulphide bond formation and glycosylation, the CHO cell lines
express glycosylated TF, which is reported to show multiple bands
with reduced samples. Size heterogeneity of recombinant TF is
due to differences in glycosylation of a single protein. The role of
post-translational glycosylation in size heterogeneity has been
confirmed by showing that reduced heterogeneity results in a
single 36-kDa band of TF, when biosynthesis is done in the pres-
ence of tunicamycin to inhibit N-linked glycosylation (Rehemtulla
et al. 1991).
TF in lung cancer cells also exhibited several bands. This may
have been caused by the presence of TF in a variety of forms with
different qualities and degrees of glycosylation and by the pres-
ence of TF as a dimeric form on the surface of cells (Fair and
MacDonald, 1987).
Immunocytochemical evaluation of TF
Two adenocarcinoma cell lines (ABC-1 and A549) and one squa-
mous cell carcinoma cell line (EBC-1) were used for immunocyto-
chemical studies of TF. Anti-TF mAb reacted strongly with ABC-1
A
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Figure 3 Immunohistochemical staining for TF in surgically resected lung cancer tissues. (A) Large cell carcinoma. All tumour cells stain brightly, and this case
is graded as strongly positive (++) (´ 84). (B) Poorly differentiated adenocarcinoma. In this case, a heterogeneous pattern of staining is observed. This case is
graded as moderately positive (+) (´ 72). (C) Moderately differentiated squamous cell carcinoma. This case is graded as moderately positive (+). TF-positive
staining among the squamous cell carcinoma cells is apparent in mature central keratinized areas (´ 36). (D) Specificity control, the same case as Figure 3 (C).
The specificity of the staining was verified by blocking this reaction by pre-absorption of the probe with purified placental TF (´ 36)476 M Sawada et al
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and EBC-1 but weakly with A549. ABC-1 cells were homo-
geneously stained along the cell membrane (Figure 2), whereas
EBC-1 cells were heterogeneously stained: some cells were stained
strongly and other cells were stained very weakly.
TF Ag in cell lysates and culture media of lung cancer
cell lines
The levels of TF Ag in cell lysates and culture media of eight cell
lines of human NSCLC were examined (Table 1). TF Ag was
detected in both cell lysates and culture media of all lung cancer cell
lines assayed. Most adenocarcinoma cell lines, except for A549,
produced high levels of TF. Five of eight NSCLC cell lines (PC-3,
ABC-1, RERF- LC-OK, RERF-LC-MS and EBC-1) were derived
from metastatic lesions or malignant cells in pleural effusion. These
cell lines produced high levels of TF (48.3 ± 23.5 ng 10—6 cells mean
– s.e.m.; range 4.52—130.68), whereas the cell lines derived from,
primary lesions (A549, LC1sq and LK2) produced low levels of TF
(0.2 ± 0.1 ng 10—6 cells; range 0.10—0.42).
Immunohistochemical studies of TF in clinical
specimens
In all cases examined, normal bronchial epithelial cells were posi-
tive for TF, staining more strongly in basally located cells, and the
adjacent submucosa was negative. Endothelia of capillaries and of
small to medium-sized blood vessels did not react at any site.
Alveolar epithelial cells, especially type II alveolar pneumocytes,
showed positive staining for TF. These results are consistent with
previous observations (Drake et al, 1989).
Lung cancer tissues from 55 patients were examined for expres-
sion of TF (Figure 3). All mAbs and pAb reacted with each of the
lung cancer specimens in a similar manner. The specificity of the
staining was verified by blocking this reaction by pre-absorption
of the probe with purified placental TF (Figure 3C and D). A
heterogenous and studded pattern of staining was sometimes
observed within the positive sections. Therefore, the specimens
were evaluated semiquantitatively by calculating the percentage of
positively stained neoplastic cells. The result of staining was
scored from (—) to (++) (see Materials and methods for details).
The relationship between TF expression and pathological char-
acteristics was analysed in each sample (Table 2). Of the 55
patients examined, 46 (84%) were positive for TF; 32 of 38 (84%)
adenocarcinomas were positive for TF, 12 of 15 (80%) squamous
cell carcinomas were positive and two of two (100%) large-cell
carcinomas showed positive staining for TF. Strongly positive
staining (++) of neoplastic cells was observed in 11 of 38 (29%)
adenocarcinomas as compared with only one of 17 (6%) other
histological types of tumours.
There was a significant difference in TF expression between the
group that was positive for haematogenous or lymphogenous
metastasis (28 patients) and the group that was negative for metas-
tasis (27 patients). Of the 28 patients who had metastasis, 26
(93%) showed positive TF expression; of the 26, 10 were strongly
positive (++) and 16 were moderately positive (+). Of the 27
patients who had no metastasis, 20 (74%) showed positive TF
expression; of the 20, only two were strongly positive (++) and 18
were moderately positive (+) (P < 0.05) (Figure 4).
DISCUSSION
Although TF has been found in several types of neoplastic cells
(Silberberg et al, 1989; Callander et al, 1992), TF expression in
lung cancer, especially in NSCLC, remains controversial.
Immunohistochemically, Callander et al (1992) examined fresh-
frozen specimens and showed that lung cancers, including NSCLC,
expressed TF. In contrast, Ornstein et al (1991) examined acetone-
methylbenzoate-xylene (AMeX)-fixed specimens and reported that
TF expression was rare among NSCLCS. Contrino et al (1996)
reported later that the previous failure to demonstrate TF expres-
sion immunohistochemically could have been due to a technical
issue related to choice of tissue fixation techniques. Therefore, we
investigated TF expression in fresh-frozen specimens to avoid this
technical problem; we detected TF expression in 46 of 55 speci-
mens of NSCLC. Furthermore, functional study (clotting time),
Western blot analysis and immunocytochemical study also indi-
cated that TF is present in NSCLC cells in culture. We therefore
conclude that NSCLC cells produce various levels of TF.
Recently, several investigators have suggested a causal relation-
ship between TF expression and the metastatic properties of
tumours. Adamson et al (1994 a,b) demonstrated that procoagulant
activity characterized as a TF—FVIIa complex reflects the malig-
nant phenotype in both human cases and an animal model of
prostate cancer. Mueller et al (1992) reported that metastatic
melanoma cells expressed higher levels of TF than did non-
metastatic cells and that inhibition of TF receptors resulted in a
significant reduction in melanoma cells retained in the lung in a
murine model. Although there are many reports on the role of TF
in tumour growth, most previous studies have included only a few
types of cell lines and studies of clinical specimens are rare.
Therefore, we measured TF in a wide variety of NSCLC cell lines
and found that human NSCLC cell lines derived from metastatic or
disseminated lesions produced high levels of TF in vitro.
Difficulties in comparing the biological properties of cell lines
with those of their original tumours and in comparing the proper-
ties of different cell lines with each other have often been
discussed. It has also been suggested that the properties of cell
lines might change with passage number and culture conditions.
For example, TF expression is rapidly induced in various types of
cells by serum containing platelet-derived growth factor, fibroblast
growth factor, transforming growth factor b and epidermal growth
factor (Mackman, 1995). Therefore, we additionally studied surgi-
cally resected specimens to further investigate the role of TF in
tumour growth and metastasis. We found a significantly stronger
staining for TF in human NSCLC specimens with metastasis than
Metastasis (+)
(n = 28)
Metastasis (–)
(n = 27)
Strongly positive (+ +), the percentage of positive neoplastic cells was over 90%.
Moderately positive (+), the percentage of positive neoplastic cells was under 90%.
Negative (–), completely negative.
0 50 100%
(P < 0.05)
Figure 4 Comparison of TF expression between groups with and without
metastasis. TF expression is significantly different between the groups
(P < 0.05)in those without metastasis, suggesting that TF is associated with
the spread of NSCLC.
The exact mechanisms by which TF is involved in metastasis
are not clear. Bromberg et al (1995) reported that metastasis
occurred in mice receiving injections of coagulation-defective TF
mutant melanoma cells, suggesting that TF promotes metastasis by
a pathway independent of blood coagulation. Zhang et al (1994)
demonstrated that transfecting an antisense DNA sequence for the
TF gene into sarcoma cells resulted in a marked reduction in their
ability to secrete vascular endothelial growth factor (VEGF); this
suggests that TF expression in tumours may have a direct or indi-
rect effect, or both, on neovascularization. On the other hand, the
effect of TF on metastasis is known to be mediated in part by prod-
ucts of the coagulation cascade. Fibrin generated around tumours
might protect malignant cells from host defence mechanisms
(Gunji and Gorelik, 1988) and thrombin might support the inva-
sion of tumour cells by degrading the subendothelial matrix
(Esumi et al, 1991). Procoagulant activity might facilitate cell
adherence to the endothelium, extravasation of tumour cells, or
proliferation of tumour cells at the site of a secondary deposit
(Gasic, 1984).
Cultured lung cancer cells examined in the present study
showed various levels of procoagulant activities. Two different
procoagulants, TF and cancer procoagulant, have been identified
as possible initiators of the coagulation cascade in malignant
disease (Gordon et al, 1975). In our study, procoagulant activities
were neutralized by preincubation of cells with an anti-TF mAb,
showing that TF contributes to the procoagulant status of lung
cancer, and may therefore promote metastatic processes caused by
products of the coagulation cascade. This contention is supported
by our finding of higher levels of TF in cell lines derived from
metastatic lesions or from malignant cells in pleural effusion.
Although we did not determine the functional capacity of TF Ag
recognized immunohistochemically in this study, Contrino et al
(1994) examined TF expression in breast cancer using the same
mAb as we used and reported that functional TF and antigenic TF
were detected in parallel in various carcinomas. Therefore, we
suggest that the TF Ag recognized immunohistochemically in this
study is functionally active and that lung cancer cells positive for
TF may have high coagulant activity, leading to high metastatic
potential.
In conclusion, NSCLC cells produced various levels of TF. TF
might modulate cancer cell behaviour and might be involved in the
spread of lung cancer. Further studies of TF may provide new
insights into the characteristics of lung cancer.
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